A Study of PM1015 in Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2024

Conditions

Advanced Solid Tumor

Interventions

DRUG

CD73 Antigen

subjects will be administered with PM1015 via intravenously (IV) Q2W pemetrexed until progression or accepted other treatment.

Trial Locations (1)

RECRUITING

Beijing Cancer Hospital, Beijing